Sec. 2. Clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers
364 words·~2 min read·
/bill/114/hr/3678/ih/section-2·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Paragraph
(3)of section 9008(e) of the Patient Protection and Affordable Care Act ( 26 U.S.C. 4001 note prec.; Public Law 111–148 ) is amended to read as follows: The term branded prescription drug sales shall not include sales of any drug or biological product— with respect to which a credit was allowed for any taxable year under section 45C of the Internal Revenue Code of 1986; with respect to which a credit was allowable for any taxable year beginning before January 1, 2011, under such section 45C (without regard to whether such credit was claimed or received); or which was any drug or biological product approved or licensed prior to January 1, 2011, by the Food and Drug Administration, for marketing solely for 1 or more rare diseases or conditions. Subparagraph
(A)shall not apply with respect to any drug or biological product after the date on which such drug or biological product is approved or licensed by the Food and Drug Administration for marketing for any indication other than the treatment of a rare disease or condition. In this paragraph, the term rare disease or condition has the meaning given such term under section 45C(d)(1) of the Internal Revenue Code of 1986. . Subsection
(b)of section 9008 of the Patient Protection and Affordable Care Act ( 26 U.S.C. 4001 note prec.; Public Law 111–148 ) is amended by adding at the end the following new paragraph: If— the fee under this section for a calendar year with respect to a covered entity (determined without regard to this paragraph), exceeds the fee that would be determined under this section for such year with respect to such entity if branded prescription drug sales of all covered entities were determined without regard to clauses
(ii)and
(iii)of subsection (e)(3)(A), then such entity's fee under this section for such calendar year shall be determined as described in subparagraph (B). . The amendments made by this section shall apply with respect to fees the annual payment date for which under section 9008 of the Patient Protection and Affordable Care Act ( 26 U.S.C. 4001 note prec.; Public Law 111–148 ) is after December 31, 2014.
Connectionstraces to 1
Traces to 1 document
U.S. Code
1 reference not yet in our index
- Pub. L. 111-148
Citation graph
cites case law
Sec. 2
Clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers
Pub. L.Pub. L. 111-148
Cites 2Cited by 0 across 0 sources